Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

TScan Therapeutics, a US-based T-cell immunotherapy developer spun out of Harvard University, has filed for an initial public offering on the Nasdaq Global Market.
The company has set a placeholder figure of $100m. Morgan Stanley, Jefferies, Cowen and Barclays Capital are underwriters for the IPO.
Founded in 2018, TScan is developing T-cell therapies to target haematological and solid tumours. Its TargetScan tool analyses cancer patients’ active T-cell receptors to genetically replicate them through its ReceptorScan technology.
The company will use the proceeds of the offering and its cash on hand to execute phase 1/2 clinical trials for three drug candidates and boost its drug discovery pipeline. It will also improve its existing platforms and increase manufacturing capabilities.
TScan’s largest shareholder is entities affiliated with Baker Bros Advisors, which own a 24.7% stake, followed by Novartis BioVentures, a corporate venturing subsidiary of pharmaceutical firm Novartis more…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in